FDA releases guidance for near infrared (NIR) analytical procedures
New final guidance will aid drug developers in developing, validating, applying and submitting near infrared (NIR) spectroscopy-based analytical procedures.
List view / Grid view
News
Cell line development services market to value $2.4 billion by 2030
New report suggests the cell line development services market will witness a 14.3 percent CAGR between 2021 and 2030.
Moderna named Best Workplace for Innovators 2021 by Fast Company
Moderna tops the 2021 Best Workplaces for Innovators list following its "epic" COVID-19 vaccine development journey and impressive growth in 2020.
Forxiga approved in EU for chronic kidney disease treatment
Forxiga’s approval, based on unprecedented Phase III data, is the most significant advancement in chronic kidney disease (CKD) treatment in over 20 years.
Pharmacovigilance Risk Assessment Committee (PRAC) meeting highlights, August 2021
The EMA's drug safety committee (PRAC) recommends updating risks of Janssen COVID-19 Vaccine, though the benefit-risk balance remains unchanged.
Libtayo® with chemotherapy trial stopped early due to success
Phase III trial of Libtayo® (cemiplimab) combined with chemotherapy stops early due to significant improvement in overall survival in lung cancer patients.
Chikungunya vaccine effective in 98.5 percent of participants
Valneva’s single-shot chikungunya vaccine induced neutralising antibody titers in 98.5 percent of participants in a Phase III study.
Global API CDMO market to value almost $140bn by 2028
Market research suggests the Asia Pacific region could soon overtake Europe and North America in the active pharmaceutical ingredient (API) contract development and manufacturing organisation (CDMO) market.
Remetinostat shows promise as a BCC treatment in Phase II study
Remetinostat, a first-in-class histone deacetylase inhibitor gel, displayed signs of clinical efficacy in patients with basal cell carcinoma.
Ritlecitinib improves scalp hair regrowth in alopecia trial
Ritlecitinib was shown to reduce scalp hair loss to less than or equal to 20 percent after six months in Pfizer’s Phase IIb/III trial.
Blood thinners reduce need for organ support in COVID-19 patients
Clinical trial shows that treating moderately ill COVID-19 patients with a full-dose blood thinner reduced their need for organ support.
Bayer to acquire Vividion Therapeutics for novel drug discovery platform
Bayer to pay $1.5 billion upfront to acquire Viridion Therapeutics, thus strengthening its small molecule capabilities and expanding its reach into new modalities.
Global pharma contract manufacturing market to value $120bn by 2027
Growth in the pharmaceutical contract manufacturing market to be driven by advanced technologies, the rising aging population and the increase in chronic disease cases, says report.
BioNTech strengthens neoantigen TCR programme with Kite acquisition
BioNTech acquires Kite’s solid tumour neoantigen T cell receptor research platform and Gaithersburg manufacturing facility for undisclosed amount.
